Auto saved by Logseq

pages/STOP2030___Web.md

@@ -13,11 +13,11 @@
 				- Develop a model for sustainable supply and costing
 				- Model the impact of different use cases and scenarios
 				- Pilot antihelmintic resistance surveillance based on genetic epidemiology
-		- ## Objetivos y logros de los proyectos STOP previos en background
+		- ## Objetivos y logros de los proyectos STOP previos (en background)
 			- Qualification at EMA for art. 58
 			- Safety of IVM up to 600μg/kg alone and in coformulation with albendazole
 			- Demonstrated efficacy agrainst T. trichiura in a pivotal trial in Sub-Saharan Africa
-		- FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016)
+		- ## FDC of ivm/alb has the lowest level of investment risk of all candidates for Combination for STH treatment (STH Drug Combinations Expert Meeting, BMGF, April 2016)
 		- Main results of previous STOP projects: ALIVE pivotal Trial
 		- Investigadores principales de cada uno de los partners
 		- Timeline y milestones (cuáles se han cumplido?)